Table 4 Adjusted odds ratios for eGFR decline during the two-year follow-up.
>30% eGFR decline | >40% eGFR decline | >50% eGFR decline | ||||
|---|---|---|---|---|---|---|
N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | |
No AKI (n = 2,737) | 313 (11.4%) | Reference | 149 (5.4%) | Reference | 70 (2.6%) | Reference |
AKI+/AKD− (n = 444) | 82 (18.5%) | 1.53 (1.16–2.01) | 48 (10.8%) | 1.69 (1.18–2.40) | 26 (5.9%) | 1.75 (1.07–2.79) |
AKD+ (n = 323) | 68 (21.0%) | 1.78 (1.30–2.40) | 50 (15.4%) | 2.62 (1.81–3.75) | 35 (10.8%) | 3.56 (2.24–5.57) |